Our preclinical studies suggest the capacity of the positron emission tomography imaging
agent 18F-fluorobenzyl triphenyl phosphonium (FBnTP) to detects early-stage small breast
tumors (e.g., DCIS), and differentiates benign from malignant masses with better accuracy
than that obtained by existing breast imaging tools.
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins